Press Releases from Panacea Biotec (2 total)
Panacea Biotec announces successful completion of Phase I/II study of its novel, …
• DengiAll induced robust, balanced neutralizing antibody responses against all the four Dengue virus serotypes.
• DengiAll has been found to be safe and well-tolerated with no serious adverse effects
• After a single-dose, more than 80% of the participants showed more than a Tri-valent response and ~95% showed a multivalent response
Panacea Biotec is excited to announce successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a…
Panacea Biotec and Refana announce landmark collaboration for Covid-19 vaccine
Panacea Biotec is advancing its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc. USA to make candidate Covid-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company based in Ireland.
The collaboration aims to bring to patients a whole inactivated virus-based vaccine for Covid-19. Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the…
